https://www.selleckchem.com/pr....oducts/liraglutide.h
INTRODUCTION Phase I and II trials provide the initial human safety and tolerability data for new drugs. However, the methods for presenting toxicity data are not standardized. Clinicians often first encounter these data at professional conferences. We sought to characterize how the burden of adverse events (AE) is reported at the largest professional conference in clinical oncology. METHODS We collected toxicity data from all lung cancer-associated phase I and II trial presentations and posters at the American Society for Clinical
Like
Comment
Share
